Cutaneous vasoconstriction (VC), a critical thermoregulatory response to cold, is generally impaired with aging. However, the effects of aging on local cooling-induced VC and its underlying mechanisms are poorly understood. We tested whether aged skin exhibits attenuated localized cold-induced VC and whether Rho kinase-mediated cold-induced VC is augmented with age. Skin blood flow was monitored with laser Doppler flowmetry (LDF) on 7 young and 7 older subjects. Cutaneous vascular conductance (CVC; LDF/mean arterial pressure) was expressed as percentage change from baseline (% CVC base ). Protocol 1: Two forearm skin sites were cooled to six temperatures (31.5-19°C) for 10 minutes each or two temperatures (29°C, 24°C) for 30 minutes each, with no age differences in the magnitude of VC. Protocol 2: Three forearm skin sites were instrumented for intradermal microdialysis and cooled to 24°C for 40 minutes. During minutes 1-5, there was no age difference in CVC responses at control sites (young: -45±6 vs. older: -46±3%, p>0.9). Adrenoceptor antagonism (yohimbine+propranolol) abolished VC in young (to +15±13%, p<0.05) but only partially inhibited VC in older subjects (to -23±6%, p<0.05). Rho kinase inhibition+adrenoceptor antagonism (yohimbine+propranolol+fasudil) abolished VC in both groups. During minutes 35-40, there was no age difference in control (young: -77±4 vs. older: -70±2%, p>0.3) or adrenoceptorantagonized responses (young: -61±3 vs. older: -55±2%, p>0.3); however, Rho kinase inhibition+adrenoceptor antagonism blocked more VC in older compared to young subjects (-19±11 vs. -35±3%, p<0.05). Although its magnitude remains unaffected, cold-induced VC becomes less dependent on adrenergic and more dependent on Rho kinase signaling with advancing age.
INTRODUCTION
Cutaneous vasoconstriction (VC) is the initial thermoregulatory response to cold exposure, effectively minimizing heat loss to the environment through two distinct mechanisms of VC. Whole-body cooling evokes sympathetic reflex VC, which is dependent on the release of norepinephrine and cotransmitters from sympathetic adrenergic axon terminals (38, 39, 40, 42) . In contrast, localized cooling of the cutaneous blood vessels and surrounding tissue engages local (i.e., non-reflex) cold-induced VC that is mediated primarily by norepinephrine at 2 -adrenoceptors (9, 12, 14, 25, 28, 32) and Rho kinase (45) , along with a proposed rebound constriction via nitric oxide withdrawal (19) .
One of the cardiovascular hallmarks of human aging is impaired vascular responsiveness to a stimulus. However, while age-associated impairments in reflex cutaneous VC in response to whole-body cooling are relatively well-understood (26, 27, 34, 42) , the effects of advancing age on local cold-induced VC are comparatively poorly characterized. To date, only one study has addressed the effects of aging on VC during local cooling (43) , concluding that there was no age difference. However, that investigation only quantified local cold-induced VC in response to 10 minutes of local cooling to 24ºC, precluding the characterization of possible age differences in VC across a wider physiological spectrum of cooling durations and magnitudes. Given that early-(0-10 min cooling) and late-phase VC (> ~20 min cooling) are mediated by different primary mechanisms (25, 32, 45) , it is entirely possible that age differences may have arisen with a longer cooling protocol. Thus, the existing data do not adequately address the question of whether (or how much) aging affects the pattern and magnitude of local cold-induced VC.
Cutaneous adrenergic desensitization occurs with aging (44) , suggesting that the norepinephrine-mediated portion of cold-induced VC may be attenuated in older subjects.
Conversely, Rho kinase-mediated VC may be augmented in older humans. Both in vitro and in vivo, Rho kinase is a key intracellular mediator directly involved in VC induced by direct tissue cooling (1, 2, 45) . However, Rho kinase activity is augmented in pro-constrictor vascular conditions commonly associated with aging, including hypertension, coronary and cerebral vasospasm, erectile dysfunction, and diabetes (6, 16, 23, 24, 29, 33, 46) . If Rho kinase-mediated VC is augmented with aging in the absence of disease, it would complement other recent findings suggesting that aging per se is associated with pre-clinical pro-constrictor signaling changes in the vasculature (5, 20, 21) . Accordingly, the purposes of the present study were to systematically characterize responses to localized cooling in young and aged skin and to investigate whether the mechanisms underlying local cold-induced VC change with aging. We hypothesized that 1) VC is blunted in aged skin as local cooling magnitude and/or duration increases, and 2) NE-mediated VC diminishes and Rho kinase-mediated VC increases in aged skin.
METHODS AND MATERIALS

Subjects
Seven young (20-27 yr; 4 men, 3 women) and 7 older (67-74 yr; 3 men, 4 women) subjects all participated in 2 experimental protocols. All younger women were tested during days 1-7 of the menstrual cycle and none were taking oral contraceptives; all older women were post-menopausal and none were taking hormone replacement therapy. All subjects underwent a standardized medical screening and were healthy, normotensive (BP<140/90 mmHg), non-obese non-smokers. No subjects were taking any medications that might alter cardiovascular responses to cooling. They abstained from alcohol and caffeine for 12 h prior to coming to the laboratory.
Approval was obtained from the Institutional Review Board of The Pennsylvania State
University. Each subject gave verbal and written informed consent prior to participation in the study, and all procedures conformed to the standards of the Declaration of Helsinki.
Protocol 1
Subjects arrived at the building at 0800 h on the morning of the experiment. After subjects assumed a supine position on the laboratory hospital bed in a temperature-controlled room (~23°C), two forearm skin sites (6.5 cm Following the insertion trauma resolution period, microdialysis sites were randomly assigned to continuously receive 1) lactated Ringers to act as control, 2) 5 mM yohimbine + 1 mM propranolol (Y+P) to antagonize -and -adrenoceptors, or 3) Y+P+3 mM fasudil (Y+P+fasudil) to simultaneously antagonize adrenoceptors and inhibit Rho kinase activity (45) .
Although yohimbine is traditionally employed as an 2 -adrenoceptor-selective antagonist, it antagonizes both 1 -and 2 -adrenoceptors at the concentration used in this study (18, 38, 39, 42) .
RBC flux, MAP, CVC, and T loc were evaluated and controlled in the same manner as described in protocol 1. and T loc was clamped at 24°C for 40 minutes, after which sites were rewarmed back to 34°C.
All drugs were obtained from Sigma-Aldrich (St. Louis, MO, USA), except fasudil, which was obtained from Tocris Bioscience (Ellisville, MO, USA). All drug solutions were mixed just prior to usage, dissolved in lactated Ringer's solution, and sterilized using syringe microfilters (Acrodisc, Pall, Ann Arbor, MI, USA).
Data collection and analysis
Data were recorded and stored as 1-minute averages using computer software (LabView) and a data acquisition system (National Instruments, Austin, TX, USA). Baseline values for normalization were determined by averaging the last 5 minutes of baseline data. In both experimental protocols, CVC values recorded during localized cooling were averaged over 5-minute intervals for analysis, except for site 1 in protocol 1, where CVC values were averaged during the last 3 minutes of each 10-minute cooling stage. In protocol 2, "early phase" VC was defined as the average of CVC values during the first 5 minutes of cooling, while "late phase" VC was defined as the average of CVC values during the last 5 minutes of cooling (minutes [35] [36] [37] [38] [39] [40] ). Student's t-tests were used to determine significant differences in physical characteristics between young and older subjects. Three-way analysis of variance (ANOVA) was conducted to detect differences in CVC responses between age groups at difference treatment sites over the duration of cooling or norepinephrine administration. Planned-comparison post-hoc tests were performed when appropriate to determine where age and treatment differences occurred. Data from young subjects in protocol 2 have been published elsewhere (45) 
RESULTS
Subjects in the two age groups were well matched for height, weight, and resting MAP (Table 1 ). In the older group, n=7 for data obtained from control sites; however, due to inadequate adrenoceptor antagonism during the norepinephrine test, n=6 for Y+P and Y+P+fasudil sites. Although mean body mass index was higher (p=0.01) in older subjects due to a non-significant tendency for older subjects to be heavier (p=0.09), body mass index was not a significant factor in preliminary statistical analyses, indicating that any observed age differences in local VC were not attributable to differences in body fat or tissue insulation.
Protocol 1
At site 1, there were no age differences in cold-induced VC responses to increasing magnitudes of short-duration local cooling (Figure 1 ). At site 2, both the pattern and magnitude of cold-induced VC in response to prolonged cooling were similar throughout the entire protocol in young and older subjects at both 29°C ( Figure 2A ) and 24°C ( Figure 2B) , with the only difference occurring at T loc =29°C during the first 5 minutes of the protocol (p=0.04).
Protocol 2
In representative time-course tracings of cold-induced VC (T loc =24°C for 40 minutes) from a young subject ( Figure 3A ) and an older subject ( Figure 3B ), the relative contributions of the underlying mechanisms mediating VC changed with aging. In the young tracing, Y+P administration attenuated cold-induced VC throughout the cooling protocol, and the addition of fasudil to the adrenoceptor blockade further inhibited VC. In the older tracing, Y+P administration did not inhibit any portion of early-phase cold-induced VC and only mildly attenuated VC as cooling progressed. However, the addition of fasudil to the adrenoceptor blockade virtually abolished VC at all time points.
Mean CVC responses to the prolonged localized cooling protocol exhibited no age differences at control sites, while there were significant age differences at both Y+P and Y+P+fasudil sites (Figure 4 
DISCUSSION
This study is the latest in a series of investigations that has characterized age-associated changes in cutaneous VC and articulated the altered mechanisms responsible for those changes.
Studies utilizing whole-body cooling concluded that reflex VC is blunted with age due to an absence of non-adrenergic VC compounded by impaired responsiveness to norepinephrine (42, 44) ; however, later work utilizing local cooling initially indicated that local VC is paradoxically preserved with age (43) , and the present study now confirms and extends those findings to suggest that this maintenance is due to an augmentation of non-adrenergic VC in spite of impaired responsiveness to norepinephrine. Specifically, the primary findings of the present study indicate that 1) regardless of temperature or duration of local cooling, the magnitude and pattern of cold-induced VC remain unchanged with aging, but that 2) the mechanisms responsible for mediating local cold-induced VC become less norepinephrinedependent and more Rho kinase-dependent in aged skin.
Magnitude of Cold-induced VC with Aging
In protocol 1, the systematic manipulations of temperature and duration of local cooling were designed to reveal whether aging affects the magnitude of, threshold for, or pattern of coldinduced VC. Documented decrements in cutaneous reflex VC function that accompany advancing age (26, 27, 34, 42) suggest that local VC may also undergo a material change with age.
However, the results of protocol 1 indicate that the magnitude and pattern of local cold-induced VC remain unchanged in aged skin. Thus, given that the magnitude of local cold-induced VC does not change with aging but that it is dictated in part by adrenergic mechanisms, which undergo desensitization in the cutaneous vasculature with advancing age (44), protocol 2 was conducted to investigate whether the underlying mechanisms of local cold-induced VC in aged skin rely less on adrenergic pathways and more on upregulated compensatory VC pathways, in particular Rho kinase.
Adrenergic Mechanisms of Cold-induced VC with Aging
During the first 10 minutes of localized skin cooling in vivo in young subjects, immediate and pronounced VC occurs that is dependent on neurally released norepinephrine and is not affected by proximal nerve blockade, suggesting a localized (i.e., non-reflex) mechanism predominantly mediated by norepinephrine of sympathetic origin binding to 2 -adrenoceptors (9, 12, 14, 25, 28, 32) . However, the effects of aging on the adrenergic portion of cold-induced VC are unknown. In the present study, young and older subjects exhibited the same degree of coldinduced VC at control sites during early phases of cooling; however, while early-phase VC in young subjects was completely inhibited by Y+P (45), early-phase VC in older subjects was only inhibited by ~50% at adrenoceptor-antagonized sites (compared to control responses), revealing a diminished adrenergic contribution to early-phase VC. This finding is supported by the observation that VC was significantly attenuated in aged skin at control sites during thermoneutral norepinephrine administration. These combined results also support and extend previous findings from our laboratory, establishing that adrenergic VC is attenuated during whole-body cooling, exogenous norepinephrine administration, and now localized cooling (42, 43, 44) .
Rho kinase Mechanisms of Cold-induced VC with Aging
Both in vitro and in vivo, Rho kinase is a key intracellular mediator directly involved in 2,3,10,15,17,36,37) . However, Rho kinase activity is augmented in proconstrictor vascular conditions commonly associated with aging, including hypertension, coronary and cerebral vasospasm, erectile dysfunction, and diabetes (6, 16, 23, 24, 29, 33, 46) , raising the question as to whether this augmentation is due solely to pathology or whether it could also be attributed, in part, to the natural aging process.
Our results from protocol 2 confirm that aging alone is associated with augmented Rho kinase-mediated VC. In contrast to young subjects, who exhibited early-phase VC that was abolished by adrenergic blockade, older subjects exhibited early-phase VC was that only partially blocked by adrenergic blockade but completely abolished by the further addition of a Rho kinase inhibitor. These results suggest that the non-adrenergic VC observed during min 1-5 at Y+P sites in older subjects was mediated by Rho kinase. As localized skin cooling progressed beyond 10 minutes, CVC continued to decrease in both age groups at both control and Y+P-treated sites, indicating the addition of non-adrenergic VC mechanism(s) to young vessels and the further contribution of non-adrenergic VC to aged vessels (19, 25, 32, 45) .
However, while there were no CVC differences between young and older subjects at control or Y+P sites, the addition of a Rho kinase inhibitor to the adrenoceptor antagonists during latephase cooling blocked significantly more late-phase VC in older subjects compared to young, suggesting that the non-adrenergic VC contributions of Rho kinase during late-phase cooling are much more pronounced in older subjects compared to young (45) . Both early-and late-phase non-adrenergic VC responses were most likely mediated by Rho kinase's direct effects on myosin light chain phosphorylation, leading to an increase in the intracellular sensitivity to extant Ca
2+
. These results suggest that augmented Rho kinase-mediated VC may be, at least in part, a function of aging per se rather than the diseases associated with aging; indeed, they complement other recent findings suggesting that aging (in the absence of overt pathology) is associated with pre-clinical pro-constrictor signaling changes in the vasculature (5, 20, 21) . These results also suggest that there is at least one other non-adrenergic mechanism that contributes to local cold-induced VC in both young and old, most likely a decrease in nitric oxide synthase activity and/or nitric oxide function (19) .
It is surprising that the magnitude of local cold-induced VC is so well-maintained throughout old age, especially considering the physiological precedent for compromised vascular function with advancing age. However, the present data suggest that while adrenergic VC may be substantially blunted in aged skin, Rho kinase-mediated VC is augmented sufficiently to compensate for impaired adrenergic VC and results in a net maintenance of local cold-induced VC with aging. It is also possible that, because some of the mechanisms driving cold-induced VC have only recently come to light (19, 45) , other as-yet-unknown vascular mediators may also contribute to the maintenance of this response with aging, as well.
There are several plausible mechanisms whereby Rho kinase-mediated VC may be augmented with aging, including 2 that are dependent on the recently documented decrease in nitric oxide bioavailability associated with advancing age. In young vessels, the nitric oxide pathway downregulates Rho kinase-mediated VC (6, 8, 35) , while activated RhoA and Rho kinase downregulate several steps in the endothelial nitric oxide synthase pathway (13, 30, 31, 41) , effectively maintaining a healthy and necessary balance between dilator and constrictor influences in the vasculature. However, healthy aging is associated with increased vascular arginase activity (5, 21) , which competes for the nitric oxide substrate, L-arginine, and can thus limit functional nitric oxide synthesis. If nitric oxide and downstream cyclic GMP (which deactivates RhoA) are diminished, there may be less appropriate inhibitory regulation of the Rho kinase pathway, leading to augmented Rho kinase activity. Aging is also associated with increased production and decreased degradation of reactive oxygen species (ROS) in the skin (7, 11) , resulting in a net age-associated increase in oxidative stress in the cutaneous vasculature.
ROS, in turn, may enhance Rho kinase-mediated VC indirectly via limitation of nitric oxide bioavailability by ROS-mediated deactivation of nitric oxide, converting it to peroxynitrite before nitric oxide can bind with soluble guanylyl cyclase (4, 20) . However, this explanation requires further testing within the context of cold-induced VC to establish its validity.
Additionally, ROS may also enhance Rho kinase-mediated VC independent of nitric oxide via direct cold-induced activation of ROS, leading to ROS-mediated activation of Rho kinase activity, as has been demonstrated in in vitro cutaneous vascular preparations (2) .
Limitations
Because ROS activity increases in response to cold and activates the RhoA/Rho kinase pathway (3), it is possible that the antioxidant properties of ascorbate (norepinephrine preservative) could have limited Rho kinase activity in the present study. However, given the small dose and short duration of ascorbate delivery (far short of what is required for adequate antioxidant administration in the vasculature), it is unlikely that sufficient ascorbate accumulated before washout to exert significant antioxidant effects on the cutaneous arterioles. Furthermore, if the minute dose of ascorbate did effect ROS and Rho kinase activity, leading to longer-term reduction in reactive oxygen species activity, its effects would be accounted for at the control site and would not confound the interpretation of data relative to control or other treated sites.
While both early-and late-phase data clearly present evidence supporting the participation of non-adrenergic Rho kinase pathways, the present study does not address whether interactions between adrenergic and Rho kinase pathways (i.e., 2C translocation) also occurred in aged skin. However, while Rho kinase significantly mediates VC through both adrenergic and non-adrenergic pathways in young subjects (45) , older subjects likely rely less on adrenergic mechanisms to effect VC than their younger counterparts. Adrenergic VC in cutaneous vasculature undergoes significant attenuation with aging due to receptor desensitization (42, 43, 44) . Those findings suggest that although Rho kinase may stimulate cold-induced 2C -adrenoceptor translocation in aged skin, age-associated impairments in adrenergic signaling compromise the downstream VC response to cold and functionally mask the interaction of the two pathways. Thus, adrenergic mechanisms, of necessity, become secondary in aged skin to any compensatory non-adrenergic mechanisms of VC.
Summary
In summary, the primary findings of this study indicate that although there is no age difference in the pattern or magnitude of local cold-induced VC after systematic manipulation of both temperature and duration of cooling, the underlying mechanisms that mediate local coldinduced VC are less adrenergic and more Rho kinase-dependent in aged skin. This conclusion is supported by both previous and present findings that cutaneous vascular responsiveness to norepinephrine is reduced with aging. The results of this study also support more general findings in the literature suggesting that augmented Rho kinase-mediated VC is associated with age-related pathologies and extend those findings to healthy cutaneous vasculature. Thus, while augmented Rho kinase-mediated VC may act as a compensatory pathway to preserve local coldmediated VC with aging, it also serves as an indicator of the increasingly pro-constrictor state of healthy aged vasculature. baseline; † P < 0.05 vs. young. Note: young data has been previously published elsewhere (45) and is presented here for comparison purposes only. (45) and is presented here for comparison purposes only. 
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